11 February 2021 - Prophylaxis study
Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration
et al., PloS ONE, doi:10.1371/journal.pone.0246825 (Peer Reviewed)
Retrospective PSM analysis of pre-existing aspirin use in the USA, showing lower mortality with treatment.
|
risk of death, 59.4% lower, RR 0.41, p < 0.001, treatment 272 of 6,300 (4.3%), control 661 of 6,300 (10.5%), NNT 16, odds ratio converted to relative risk, 30 days, PSM.
|
|
risk of death, 60.5% lower, RR 0.40, p < 0.001, treatment 170 of 6,814 (2.5%), control 427 of 6,814 (6.3%), NNT 27, odds ratio converted to relative risk, 14 days, PSM.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Osborne et al., 2/11/2021, retrospective, propensity score matching, USA, North America, peer-reviewed, 6 authors.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.